National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Ewing Family of Tumors Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 12/05/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Ewing Tumor of Bone: Localized Tumors






Ewing Tumor of Bone: Metastatic Tumors






Ewing Tumor of Bone: Recurrent Tumors






Get More Information From NCI






Changes to This Summary (12/05/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Cellular Classification

Cytogenetic Changes in the Ewing Family of Tumors

Ewing family of tumors (EFT) belong to the group of neoplasms commonly referred to as small, round, blue-cell tumors of childhood. The MIC2 gene product, CD99, is a surface membrane protein that is expressed in most cases of EFT and is useful in suggesting diagnosis of these tumors when the results are interpreted in the context of clinical and pathologic parameters.[1] MIC2 positivity is not unique to EFT, and positivity by immunochemistry is found in several other tumors including synovial sarcoma, non-Hodgkin lymphoma, and gastrointestinal stromal tumors. Concurrent positivity for membrane CD99 and FL-1 strongly suggest the diagnosis of EFT.[1] The detection of a translocation involving the EWS gene on chromosomes 22 band q12 and any one of a number of partner chromosomes is the key feature in the diagnosis of EFT.[2]

The individual cells of EFT contain round-to-oval nuclei with fine dispersed chromatin without nucleoli. Occasionally, cells with smaller, more hyperchromatic, and probably degenerative nuclei are present giving a light cell/dark cell pattern. The cytoplasm varies in amount, but in the classic case it is clear and contains glycogen, which can be highlighted with a periodic acid-Schiff (PAS) stain. The tumor cells are tightly packed and grow in a diffuse pattern without evidence of structural organization. Tumors with the requisite translocation that show neuronal differentiation are not considered a separate entity, but rather, part of a continuum of differentiation.

Cytogenetic Changes in the Ewing Family of Tumors

Cytogenetic studies of the EFT have identified a consistent alteration of the EWS locus on chromosome 22 band q12 that may involve other chromosomes, including 11 or 21.[3] Characteristically, the amino terminus of the EWS gene is juxtaposed with the carboxy terminus of another gene. In most cases (90%), the carboxy terminus is provided by FLI1, a member of the Ets family of transcription factors gene located on chromosome 11 band q24. Other Ets family members that may combine with the EWS gene in order of frequency are ERG, located on chromosome 21; ETV 1, located on chromosome 7; and E1AF, located on chromosome 17; these result in the following translocations: t(21:22),[4] t(7;22), and t(17;22), respectively. Besides these consistent aberrations involving the EWS gene at 22q12, additional numerical and structural aberrations have been observed in EFTs, including gains of chromosomes 2, 5, 8, 9, 12, and 15; the nonreciprocal translocation t(1;16)(q12;q11.2); and deletions on the short arm of chromosome 6. A molecular test (i.e., reverse transcription polymerase chain reaction [RT-PCR] and restriction analysis of PCR products), currently available on a research basis only, now offers the opportunity of markedly simplifying the definition of the EFT.[5,6] The molecular assay can be performed on relatively small amounts of tissue obtained by minimally invasive biopsies and is capable of providing results faster than cytogenetic analysis.

References

  1. Parham DM, Hijazi Y, Steinberg SM, et al.: Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol 30 (8): 911-8, 1999.  [PUBMED Abstract]

  2. Delattre O, Zucman J, Melot T, et al.: The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331 (5): 294-9, 1994.  [PUBMED Abstract]

  3. Urano F, Umezawa A, Yabe H, et al.: Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis. Jpn J Cancer Res 89 (7): 703-11, 1998.  [PUBMED Abstract]

  4. Hattinger CM, Rumpler S, Strehl S, et al.: Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 24 (3): 243-54, 1999.  [PUBMED Abstract]

  5. Meier VS, Kühne T, Jundt G, et al.: Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. Diagn Mol Pathol 7 (1): 29-35, 1998.  [PUBMED Abstract]

  6. Dagher R, Pham TA, Sorbara L, et al.: Molecular confirmation of Ewing sarcoma. J Pediatr Hematol Oncol 23 (4): 221-4, 2001.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov